Oncology

The therapeutic landscape in non-muscle-invasive bladder cancer (NMIBC) is advancing with the investigation of new treatment…

Treatment of early breast cancer (eBC) is continuing to advance, and pivotal Phase III trial data released at the San Antonio Breast…

Data presented at the European Society for Medical Oncology (ESMO) Congress 2025 signal a potential shift in the management of early-stage…

Treatment for advanced non-small cell lung cancer (NSCLC) with activating mutations in HER2 relies on chemo-immunotherapy in the…

Dr. Joshua Sabari explores recent advances in the treatment of HER2-mutant non-small cell lung cancer, including a newly FDA-approved option…

The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized endocrine therapies…

Patients with cancer often have a compromised immune system, which places them at an increased risk of infection that can extend beyond…